Moderna's COVID vaccine approved by EU regulator for use on children aged 12-17
The Hague, Netherlands/ IBNS: Moderna's coronavirus vaccine has been approved by the European regulator for use on children aged 12 to 17, making it the second jab to be administered on adolescents in the continent.
"The use of the Spikevax vaccine in children from 12 to 17 years of age will be the same as in people aged 18 and above," the European Medicines Agency (EMA) told media, using Moderna's brand name.
The vaccine will be given in two shots, each four weeks apart.
The decision by the Amsterdam-based agency follows the approval of the first vaccine for European youngsters, by Pfizer/BioNTech in May.
"The study showed that Spikevax produced a comparable antibody response in 12-17-year-olds to that seen in young adults aged 18 to 25 years," it said.
The EU on Thursday said 200 million Europeans have been fully vaccinated, more than half of the adult population.
However, it is still short of the 70 percent target it had set for the summer.